Notícias

CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the initial launch of CASGEVY and prepares for data from multiple pipeline programs over the next 12 to 18 months. Speaking at a Bank of America fireside chat host

Vertex Pharmaceuticals' first quarter results reflected balanced growth across its cystic fibrosis franchise and newly launched therapies, with management highlighting commercial momentum in both established and emerging product areas. CEO Reshma Kewalramani pointed to "strong revenue growth as we reach more patients with more products," emphasizing milestone achievements for AlifTrack, KASJEVY, and Gernavix. The company also attributed performance to broader label eligibility and successful int

Halozyme Therapeutics (HALO) posted stronger-than-expected Q1 results, with revenue beating consensu

Vertex Pharmaceuticals (NasdaqGS:VRTX) has agreed Germany's first sustainable access deal for CASGEVY, a gene therapy for severe sickle cell disease and transfusion dependent beta thalassemia. The agreement with GKV-Spitzenverband aims to secure long term, reimbursed access to this one time treatment for eligible patients across the German statutory health system. This adds to Vertex's broader reimbursement progress for CASGEVY in multiple countries, expanding global reach beyond its...

Entrada Therapeutics (NASDAQ:TRDA) said initial data from the first cohort of its phase I/II ELEVATE-44-201 trial showed favorable safety and tolerability and early functional improvement in ambulatory patients with Duchenne muscular dystrophy, or DMD, who have mutations amenable to exon 44 skipping

Vertex's new drugs are gaining momentum as Alyftrek tops $1 billion in sales and Journavx prescriptions accelerate.

Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ) came out with its first-quarter results last week, and we wanted to...

Wondering if Vertex Pharmaceuticals at around US$424 per share is still a solid opportunity or if the easy gains are behind it? This article focuses squarely on what the current price might represent for you. The stock has had a mixed run, with a 1.3% decline over the last week, a 3.3% decline over the last month, a 6.1% decline year to date and a 5.7% decline over the past year, set against longer term returns of 23.1% over three years and 99.2% over five years. Recent coverage of Vertex...

The market wasn't impressed by its latest quarterly update.

Vertex Pharmaceuticals' (VRTX) management remains confident in its emerging renal franchise, suggest

Vertex tops Q1 estimates as revenues climb 8% on strong CF drug demand and new product gains. Its pipeline has advanced and its 2026 guidance reaffirmed.

Entrada Therapeutics (TRDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

US equity futures were higher pre-bell Tuesday as traders kept a close watch on the potential re-esc

CRSP posts a wider Q1 loss and revenues miss, pressuring shares, even as Casgevy sales grow and cash reserves strengthen from recent financing.

US equity futures were higher pre-bell Tuesday as traders kept a close watch on the potential re-esc

While overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug Journavx missed analyst estimates by double-digit percentages.

Moby summary of Vertex Pharmaceuticals Incorporated's Q1 2026 earnings call

Vertex Pharmaceuticals (NASDAQ:VRTX) reported first-quarter 2026 total revenue of $2.99 billion, up 8% year over year, as growth in its cystic fibrosis (CF) franchise and contributions from newer launches helped drive results. CEO and President Dr. Reshma Kewalramani said the company is “off to a te

Vertex Pharmaceuticals Incorporated is off to a terrific start in 2026, which we see as a year defined by execution. Q1 revenue growth was strong across the portfolio as we reach more patients with more products and delivered total product revenue of $2.99 billion, reflecting 8% growth year over year. Another highlight in Q1 was that products from the new disease areas, namely KASJEVY and GERNAVICS, drove approximately 25% of total product revenue growth.

The headline numbers for Vertex (VRTX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Vertex (VRTX) delivered earnings and revenue surprises of +5.76% and +0.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Vertex stock dipped late Monday on a mixed first-quarter report. But Vertex Pharmaceuticals kept its 2026 outlook.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 7.8% year on year to $2.99 billion. The company expects the full year’s revenue to be around $13.03 billion, close to analysts’ estimates. Its non-GAAP profit of $4.47 per share was 3.8% above analysts’ consensus estimates.

May 4 (Reuters) - Vertex Pharmaceuticals on Monday beat Wall Street estimates for first-quarter adjusted profit, helped by a near eight-fold surge in sales of its new cystic fibrosis treatment.

In addition to this commercialization focus, research and clinical progress remain paramount. Before I cover R&D highlights for the quarter, I would like to acknowledge our CSO, David Altshuler's retirement a year from now and the planned CSO transition to Mark Bunnage, our current SVP and Global Head of Research.

Moderna jumps despite a Q1 loss as strong international vaccine sales drive revenue surge and boost investor sentiment.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results this Monday after the bell. Here’s what investors should know.

Recently, Vertex Pharmaceuticals reported that director Suketu Upadhyay will leave its board at the 2026 annual meeting while the US FDA approved expanded use of ALYFTREK for cystic fibrosis patients aged 6 and older. At the same time, Bank of America reaffirmed Vertex as a top large-cap biotech pick, underscoring how its cystic fibrosis cash flows are supporting a broader pipeline that now includes a rare kidney disease franchise. We’ll now examine how the FDA’s expanded ALYFTREK approval...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ranks among the most profitable biotech stocks to buy now. On April 13, TD Cowen reaffirmed its Buy rating and $96 price target for Halozyme Therapeutics, Inc. (NASDAQ:HALO). The firm forecasts Halozyme to continue to outperform expectations and enhance guidance due to strong growth catalysts such as Vyvgart Hytrulo, Darzalex Faspro, […]